ReviewCancers2021
Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 139 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
139 citing papers in PubMed, 3 syntheses or guidelines pooled it, 212 citations in OpenAlex.
- Pooled it
- Pooled it
- Efficacy and safety of Toliparibumab for the treatment of non-small cell lung cancer: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study.Targeted oncology · 2023Trial
- Immunoregulatory role of quercetin in lung cancer.Cell death discovery · 2026Article
- S100A10 promotes tumorigenesis and metastasis in lung adenocarcinoma by regulating JUND/TNC axis-mediated EMT.Translational oncology · 2026Article
- Gymconopin C exhibits anti-non-small cell lung cancer effect by regulating miR-6777-5p/ADRB2 pathway to promote mitophagy.Journal of advanced research · 2026Article
- Single-cell and bulk transcriptomic profiling of metabolism-related lncRNAs reveals tumor heterogeneity and prognostic markers in non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Core Substances and Related Bio-Activities on Anti-Lung Cancer Cell A549 ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Treatment Patterns Across Lines of Therapy for Advanced Non-Small Cell Lung Cancer in the United States.Cancer medicine · 2026Article
- Ubiquitination and deubiquitination as critical modulators of NSCLC tumorigenesis and drug resistance.Discover oncology · 2026Review
- Patient profiles, incidence and trends of lung cancer in Ethiopia from 2012 to 2023 using a cancer registry.Scientific reports · 2026Article
- Targeting the Uncommon: A Case Report of Osimertinib Response in Advanced NSCLC Patient with Dual EGFR (E701fs and L702fs) Frameshift Deletions.Current oncology (Toronto, Ont.) · 2026Article
- Lung Cancer in Never-Smokers: Risk Factors, Driver Mutations, and Therapeutic Advances.Diagnostics (Basel, Switzerland) · 2026Review
- Cycling Through Uncertainty: The Psychological Experiences of Individuals With Lung Cancer Receiving Immunotherapy And/Or Targeted Therapy.Psycho-oncology · 2026Article
- Fuscan: a robust DNA fusion caller for targeted sequencing data in cancer diagnostics.Bioinformatics advances · 2026Article
- Case Report: Short-term disease control with subsequent icotinib therapy in EGFR L858R/C797S, T790M-negative lung adenocarcinoma after osimertinib resistance.Frontiers in oncology · 2026Article
- Biomarker analysis from a Phase 1/1b study of tusamitamab ravtansine in patients with advanced non-small cell lung cancer.Translational oncology · 2026Article
- NGS-Based Mutation Profiling and PD-L1 Expression in NSCLC Patients: A Single-Centre Prospective Analysis.Turk patoloji dergisi · 2026Article
- Nanomedicine initiates ferroptosis for enhanced lung cancer therapy.Drug delivery · 2025Review
79 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Non-small cell lung cancer (NSCLC) is a subtype of the most frequently diagnosed cancer in the world. Its epidemiology depends not only on tobacco exposition but also air quality. While the global trends in NSCLC incidence have started to decline, we can observe region-dependent differences related to the education and the economic level of the patients. Due to an increasing understanding of NSCLC biology, new diagnostic and therapeutic strategies have been developed, such as the reorganization of histopathological classification or tumor genotyping. Precision medicine is focused on the recognition of a genetic mutation in lung cancer cells called "driver mutation" to provide a variety of specific inhibitors of improperly functioning proteins. A rapidly growing group of approved drugs for targeted therapy in NSCLC currently allows the following mutated proteins to be treated: EGFR family (ERBB-1, ERBB-2), ALK, ROS1, MET, RET, NTRK, and RAF. Nevertheless, one of the most frequent NSCLC molecular sub-types remains without successful treatment: the K-Ras protein. In this review, we discuss the current NSCLC landscape treatment focusing on targeted therapy and immunotherapy, including first- and second-line monotherapies, immune checkpoint inhibitors with chemotherapy treatment, and approved predictive biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.